Regeneron Pharmaceuticals
REGN
437 hedge funds and large institutions have $20.9B invested in Regeneron Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 177 increasing their positions, 145 reducing their positions, and 38 closing their positions.
63% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 38
22% more repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 145
6% more funds holding
Funds holding: 414 → 437 (+23)
8% less call options, than puts
Call options by funds: $344M | Put options by funds: $372M
13% less capital invested
Capital invested by funds: $24B → $20.9B (-$3.04B)
46% less funds holding in top 10
Funds holding in top 10: 13 → 7 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$188M |
| 2 |
DCP
DSM Capital Partners
Palm Beach Gardens,
Florida
|
+$104M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$92.1M |
| 4 |
O
OrbiMed
New York
|
+$64.9M |
| 5 |
Teacher Retirement System of Texas
Austin,
Texas
|
+$54.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$492M |
| 2 |
JP Morgan Chase
New York
|
-$203M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$59M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$58.9M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$55.8M |
REGN Hedge Fund Activity: Q4 2013 in Review
437 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2013, worth a combined $20.9B — down 13% from $24B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new REGN positions and 38 closed out — a net gain of 24 holders — while 177 added to existing stakes and 145 trimmed.
The largest buyer was UBS AM, adding an estimated $188M. The largest seller was Fidelity Investments, cutting an estimated $492M.
- 437 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2013, up from 414 in Q3 2013.
- Funds reported $20.9B of Regeneron Pharmaceuticals stock for Q4 2013, down 13% quarter-over-quarter.
- 62 funds opened new Regeneron Pharmaceuticals positions in Q4 2013 and 38 closed out, a net change of +24 holders.
- The largest Regeneron Pharmaceuticals buyer in Q4 2013 was UBS AM, an estimated $188M added.
- The largest Regeneron Pharmaceuticals seller in Q4 2013 was Fidelity Investments, an estimated $492M sold.
Based on aggregated 13F filings for Q4 2013.